This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A monthly treatment from Otsuka reduced by more than half the levels of a toxic protein in the urine of patients with an autoimmune kidney disease. The results presented Friday achieved the interim goal of a Phase 3 study and were numerically superior to study results posted Monday by competitor Vera Therapeutics. The Otsuka drug, called sibeprenlimab, lowered proteinuria levels by 50.2% after nine months compared to an increase of 2.1% in patients given a placebo.
Skip to main content CONTINUE TO SITE ➞ Dont miss the most important voices in pharma Let PharmaVoices free newsletter keep you informed on what industry leaders are saying, straight from your inbox. By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime. Voices Q&A Profiles Biotech Spotlight First 90 Days Opinions Topics Biotech Commercialization Leadership Manufacturing Patient Pharma Policy & Regulation Research & Deve
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterised by scarring of lung tissue, leading to impaired lung function and respiratory symptoms. The emerging therapies aim to address unmet needs in IPF management by targeting specific fibrotic pathways. Therapies such as LYT-100 by PureTech, currently in Phase IIb clinical trials, show promise in potentially offering improved efficacy and safety profiles, as it is a deuterated form of pirfenidone, which allows it
Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, happy Friday! Let’s get into the news. Otsuka tops Vera Therapeutics in kidney disease study showdown From STAT’s Adam Feuerstein: Another example of why biotech is a tough business.
Dr Saloni Wagh, Managing Director, and Shivani Wagh, Joint Managing Director of Supriya Lifescience, have been named in the 2025 Candere Hurun India Women Leaders List. The list, compiled by Candere and Hurun India, features 95 women leaders who have demonstrated business leadership and contributed to the Indian economy. The 2025 edition of the list follows the theme “Celebrating Women Creating Opportunities.
87
87
Signup to get articles personalized to your interests!
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Dr Saloni Wagh, Managing Director, and Shivani Wagh, Joint Managing Director of Supriya Lifescience, have been named in the 2025 Candere Hurun India Women Leaders List. The list, compiled by Candere and Hurun India, features 95 women leaders who have demonstrated business leadership and contributed to the Indian economy. The 2025 edition of the list follows the theme “Celebrating Women Creating Opportunities.
Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh
Recently, in a significant shift toward accessible, patient-driven health care, the Food and Drug Administration approved the first at-home cervical cancer screening test. This decision supports a growing trend toward decentralizing health services and empowering people to have more control over their health screenings and tests. It may also offer revive the debate over at-home sexual assault kits (SAKs), at a time when states and companies selling these kits are battling over their legality.
Osivax has announced the completion of patient visits in its phase 2a trial evaluating a booster dose of OVX836, a broad-spectrum influenza A vaccine candidate. The final results from the trial are expected in the second half of 2025. Conducted at the centre for vaccinology (CEVAC), Ghent University Hospital, Belgium, the trial investigated the safety […] The post Osivax reaches key milestone in phase 2a trial for broad-spectrum flu vaccine appeared first on Pharmafile.
A flu vaccination walk-in finder that will help patients easily look up where they can walk into a community pharmacy to have a vaccine is to launch later this year, NHS England has announced. In its new urgent and emergency care plan 2025/26, NHS England has unveiled plans for a ‘flu walk-in finder’ in a […] The post Pharmacy flu vaccination ‘walk-in finder’ to launch later this year appeared first on The Pharmacist.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
New data from 18 abstracts, including five oral presentations, will be presented at the 33rd congress of the International Society on Thrombosis and Haemostasis (ISTH) in Washington D.C., US from June 21 to 25, 2025, highlighting Sanofi as a leader in hemophilia committed to rare blood diseases. Data to be presented expand on the potential of rilzabrutinib to address the underlying immune dysregulation of immune thrombocytopenia (ITP) and strengthen Sanofi as a leader in hemophilia with ALTUVIII
Almost 20 million patients a year could be treated in England by expanding Pharmacy First to a similar service to Scotland, according to analysis from the National Pharmacy Association (NPA). A report published by Public Health Scotland in May found that 35% of the Scottish population (1,895,836) used Pharmacy First Scotland in the most recent […] The post Call to expand England’s Pharmacy First service in line with Scotland appeared first on The Pharmacist.
Skip to content Who We Are CPA President & Vice President CPA Council CPA Team Alliances Member Associations Partners Patrons Fellows Strategy Our Impact Join Careers Our Work AMR COVID-19 CPD PharmAid Tools and Resources Latest Events News Blog Publications Support Us Contact Menu Who We Are CPA President & Vice President CPA Council CPA Team Alliances Member Associations Partners Patrons Fellows Strategy Our Impact Join Careers Our Work AMR COVID-19 CPD PharmAid Tools and Resources L
Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Some friends and I discussed V.S. Ramachandran’s famous “mirror box” therapy over drinks last night, which has long been one of my favorite experiments. It alleviates phantom limb pain, using only a mirror.
Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh
Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.
The alliance leverages both companies’ experience in the field of biosimilars. By combining their resources, they aim to expedite the development process while expanding the product’s availability worldwide. Alvotech chairman and CEO Róbert Wessman said: “We are very pleased to enter into this collaboration for pembrolizumab with Dr. Reddy’s. This agreement demonstrates Alvotech’s ability to leverage its dedicated R&D and manufacturing platform for biosimilars, accelerating the expansi
Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh
Juan Ovalles, MD, PhD, discusses how high placebo response rates driven by background therapy complicate lupus drug trials, and outlines evolving strategies in trial design, clinical practice, and pharmacist-led care to ensure investigational biologics are fairly evaluated and appropriately used in systemic lupus erythematosus.
In the second part of her Pharma Commerce video interview, Maggie McCullough, PolicyMap’s CEO, details what the company’s data reveals about the relationship between pharmacy access and broader health disparities in underserved communities.
Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.
Gene therapy experts and advocates warning of the sector’s many challenges found a receptive audience in FDA leadership at a regulatory forum Thursday.
Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh
New positive interim trial data has demonstrated that a potential best-in-class gene therapy can provide meaningful functional improvements in Duchenne muscular dystrophy. These new findings are from the Phase I/II AFFINITY DUCHENNE clinical trial for RGX-202. With a differentiated microdystrophin construct, the treatment can encode key regions of naturally occurring dystrophin, including the C-Terminal (CT) domain.
Researchers at Chiba University, Japan, alongside Niagen Bioscience, have reported successful results from the world’s first trial of nicotinamide riboside (NR), vitamin B3 derivative, for the treatment of Werner syndrome (WS), a rare genetic disorder. The study found that it enhances cardiovascular, skin and kidney health in patients, offering treatment potential for a disease which […] The post Trial into rare genetic disease Werner syndrome reports promising results appeared first on Ph
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
The global cell therapy market is projected to reach $20.07 billion by 2030, driven by the rising demand for off-the-shelf therapies that offer scalable, standardised solutions for treating a wide range of diseases, including cancer and auto-immune diseases. 1 One promising approach involves natural killer (NK) cells derived from induced pluripotent stem cells (iPSCs) which provide a renewable, genetically stable cell source capable of precise engineering for enhanced therapeutic functionality.
BioNTech and Bristol Myers Squibb (BMS) have entered a partnership to collaboratively develop and commercialise BNT327, BioNTech’s bispecific antibody, to treat multiple solid tumour types. BNT327 targets two established immuno-oncology pathways, PD-L1 and VEGF-A, to enhance tumour targeting and modulate the tumour microenvironment. It is currently in phase 3 trials for small cell and non-small […] The post BioNTech and Bristol Myers Squibb collaborate on bispecific antibody for solid tumo
Today’s guest post comes from Logan Melchione, VP of Patient Affordability at Paysign. Logan explores how maximizers have reshaped the patient affordability landscape and pressured pharmaceutical manufacturers to adapt their copay strategies. In this guest post, she outlines her perspective on the limitations of traditional copay solutions, describes Paysign’s data-driven approach to first-fill identification of maximizer impact, and shares how the company reports saving millions while improving
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
220 
Let's personalize your content